<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744767</url>
  </required_header>
  <id_info>
    <org_study_id>184/14</org_study_id>
    <nct_id>NCT03744767</nct_id>
  </id_info>
  <brief_title>Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration</brief_title>
  <official_title>Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Irmela MANTEL</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye Hospital Jules Gonin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-comparative, mono-center pilot study. Patients with neovascular age-related&#xD;
      macular degeneration (nAMD), responding insufficiently to the maximal standard care with&#xD;
      monthly intravitreal anti-VEGF injections are given adjuvant oral mineralocorticoid receptor&#xD;
      antagonists for 4 months and observed for any changes in vision or retinal structure during&#xD;
      the 4 months of adjuvant treatment, plus 2 additional months without adjuvant treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis Systemic anti-Mineralocorticoid-Receptor treatment may be a valuable adjuvant&#xD;
      treatment in anti-VEGF refractory nAMD, potentially allowing for better absorption of the&#xD;
      exudative fluid.&#xD;
&#xD;
      Aim To estimate the effect of systemic anti-Mineralocorticoid-Receptor treatment on eyes with&#xD;
      nAMD which have remained exudative despite monthly anti-VEGF treatment for at least 6 months&#xD;
      prior to enrolment.&#xD;
&#xD;
      Objectives Primary objective&#xD;
&#xD;
        -  To calculate the changes induced in retinal thickness following adjunct systemic&#xD;
           anti-Mineralocorticoid-Receptor treatment Secondary objective&#xD;
&#xD;
        -  To calculate the changes induced following adjunct systemic&#xD;
           anti-Mineralocorticoid-Receptor treatment in the following ocular parameters&#xD;
&#xD;
             -  Thickness of the neuro-retina (foveal)&#xD;
&#xD;
             -  Amount of subretinal fluid (foveal and highest elevation)&#xD;
&#xD;
             -  Height of retinal pigment epithelium detachment (foveal and highest elevation)&#xD;
&#xD;
             -  Central (Subfoveal) choroidal thickness, and at 500um nasal and temporal to the&#xD;
                fovea&#xD;
&#xD;
             -  Presence / absence of exudative signs on OCT, according to the type of fluid&#xD;
                (intraretinal cysts, subretinal fluid)&#xD;
&#xD;
             -  Best corrected visual acuity (number of letters)&#xD;
&#xD;
      Medications:&#xD;
&#xD;
      Standard medical treatment (monthly intravitreal injections with anti-VEGF) will be continued&#xD;
      during this trial, no current medications will be altered. The medication spironolactone, an&#xD;
      MR antagonist will be added to the currently prescribed medications (phase IV). The standard&#xD;
      dose of 50mg once daily per os will be prescribed for 3 months (first week 25mg only for&#xD;
      treatment introduction and safety), tapered during month 4 (25mg once daily).&#xD;
&#xD;
      In the case of a patient current taking a medication with contra-indications for this drug,&#xD;
      then the conflicting medication will be exchanged for an equivalent treatment option, where&#xD;
      this is not possible then these patients will be excluded from the study. The patient will be&#xD;
      withdrawn from the study in case of any serious side effects attributable to spironolactone&#xD;
      (increased K+ above 5.5mmol/l).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2014</start_date>
  <completion_date type="Actual">September 22, 2015</completion_date>
  <primary_completion_date type="Actual">September 22, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>all participants receive fixed monthly intravitreal anti-VEGF injections for 6 months, plus adjuvant treatment during 4 months, followed by 2 months without adjuvant treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal thickness change</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>retinal thickness in micrometers measured from the internal limiting membrane (ILM) to Bruch's membrane on optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>on ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central retinal thickness</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>automatic values from SD-OCT after segmentation correction, in micrometers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central retinal volume</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>automatic values from SD-OCT after segmentation correction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>foveal retinal thickness</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>manual measurement in micrometers from ILM to Bruch membrane at the fovea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum neuroretinal thickness with cystic changes</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>manual measure in micrometers from ILM to outer segments of photoreceptors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subretinal fluid thickness</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>manual measure in micrometers between outer segment layer and pigment epithelium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pigment epithelium detachment height</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>manual measure in micrometers from the RPE layer to Bruch's membrane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subfoveal choroidal thickness</measure>
    <time_frame>Month 3, Month 6</time_frame>
    <description>manual measure in micrometers on enhanced depth OCT imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Single treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 50 MG</intervention_name>
    <description>oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4</description>
    <arm_group_label>Single treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of neovascular age-related macular degeneration, as confirmed on angiography&#xD;
             by a retinal specialist (IM or AA)&#xD;
&#xD;
          -  Aged more than 50 years (inherent to AMD)&#xD;
&#xD;
          -  Unresponsive to maximal (monthly) anti-VEFG treatment (Ranibizumab or Aflibercept) for&#xD;
             at least 6 months: persistant intra- or subretinal fluid on spectral domain optical&#xD;
             coherence tomography at each visit 1 month after last injection.&#xD;
&#xD;
          -  Treatment with anti-VEGF for nAMD for at least 12 months&#xD;
&#xD;
          -  No contra-indications for adjunctive Spironolactone treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confounding retinal pathology eg. myopic chorioretinopathy, diabetic retinopathy,&#xD;
             vascular occlusion, retinal dystrophy and other retinal pathology&#xD;
&#xD;
          -  Polypoidal choroidal vasculopathy&#xD;
&#xD;
          -  Vitreomacular traction&#xD;
&#xD;
          -  Poor quality OCT (image quality does not allow the grading / measures on OCT)&#xD;
&#xD;
          -  High arterial pressure (&gt;160/100)&#xD;
&#xD;
          -  K+&gt;5.0 mmol/l at baseline&#xD;
&#xD;
          -  Na+ &lt;135 mmol/l at baseline&#xD;
&#xD;
          -  Creatinine clearance under 30mL/min (calculation :&#xD;
             coefficient*(140-age)*weight/creatinine in the serum; coefficient = 1.23 for males and&#xD;
             1.04 for females)&#xD;
&#xD;
          -  Acute renal failure&#xD;
&#xD;
          -  Renal dialysis&#xD;
&#xD;
          -  Non-specified renal problem&#xD;
&#xD;
          -  Arrhythmia&#xD;
&#xD;
          -  Cardiovascular comorbidity with thromboembolic risk&#xD;
&#xD;
          -  Known hypersensitivity to Spironolactone&#xD;
&#xD;
          -  Ongoing medication with eplerenone (InspraÂ®)&#xD;
&#xD;
          -  Decompensated hepatic cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Eye Hospital Jules Gonin</investigator_affiliation>
    <investigator_full_name>Dr Irmela MANTEL</investigator_full_name>
    <investigator_title>lead consultant, Head of the medical retina service, Principal Investigator, Privatdocent</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

